European and Indian Pharmacopoeias Coordinate on Quality Standards

News
Article

Representatives from the two pharmacopeias held a symposium on European and Indian legislation and regulatory requirements regarding the quality of drugs.

The European Directorate for the Quality of Medicines and Healthcare (EDQM), the European Pharmacopoeia Commission (Ph. Eur.), and the Indian Pharmacopoeia Commission (IPC) held a symposium on April 26 in Mumbai to discuss how the two pharmacopeias could work together to pool resources to improve quality standards for medicines and to harmonize activities.

The IPC has had Observer status since 2016 and has participated in Ph. Eur. Commission working groups. The symposium was attended by authorities and manufacturers of APIs.

An overview of reference standards policies and processes was presented as well as advice on how to interpret European Pharmacopoeia general chapters and monographs. To address the complex nature of global API sourcing, EDQM’s Procedure for Certification of Suitability (CEP), which offers industry and regulators a centralized procedure for accessing highly regulated markets, was discussed.

“The collaboration between the two Pharmacopoeias shows the commitment on both sides in making the best scientific resources available for the protection of health in India, in Europe and the rest of the world,” stated Susanne Keitel, PhD, director of EDQM, in a press release. “In today’s globalised pharmaceutical industry with complex supply chains, new risks and challenges, the cooperation and interaction with its Observers is crucial for the Ph. Eur. With the Indian pharmaceutical industry leading in the provision of high quality generics to the world, IPC is one of our most prominent partners,” Keitel said.

Source:

EDQM

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes